In this study, inactivation of p110δ in p110δ-high CRPC cells suppressed PI3K-AKT signaling and inhibited cell proliferation, suggesting p110δ inhibitors may prove to hold therapeutic efficacy against p110δ-high prostate cancer [58]. This evidence concerns the gene PIK3CA and prostate cancer.